Supplement Industry Must Step Up As Adulteration Threat Grows – FDA
This article was originally published in The Tan Sheet
Executive Summary
The supplement industry has not done enough to aid FDA in pursuing firms adulterating products with drugs or getting the message out about adulteration, the agency says. Increased vigilance is needed especially as bad actors become more sophisticated and expand their adulteration activities.
You may also be interested in...
U.S. Military Investigates Supplement Ingredient DMAA, Bans Sales
DoD suspends DMAA sales at military stores after regulators in Canada and New Zealand restricted access and as some U.S. firms change how they market and label the ingredient. These moves and the potential for an FDA review could lead to enforcement against DMAA similar to the 2004 ban against ephedra’s use in supplements.
U.S. Military Investigates Supplement Ingredient DMAA, Bans Sales
DoD suspends DMAA sales at military stores after regulators in Canada and New Zealand restricted access and as some U.S. firms change how they market and label the ingredient. These moves and the potential for an FDA review could lead to enforcement against DMAA similar to the 2004 ban against ephedra’s use in supplements.
GAO Adulteration Report Points To Disconnect Among FDA Offices
Food and drug attorneys critique the Government Accountability Office’s report on FDA’s efforts to counter economically motivated adulteration, which calls for greater cross-agency collaboration.